Discontinued — last reported Q4 '25
Financing
Share Buybacks
Royalty Pharma Share Buybacks decreased by 37.8% to $50.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 92.9%, from $708.78M to $50.10M.
Analysis
StatementCash Flow Statement
SectionFinancing
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2014
Last reportedQ4 2025
How to read this metric
High repurchases often signal management's confidence in the company's valuation or a strategy to improve earnings per share.
Detailed definition
The cash outflow associated with the company buying back its own shares from the open market. This is a primary method f...
Peer comparison
Common among mature, cash-generative companies; peers in the healthcare sector often balance this with R&D investment.
Metric ID:
share_repurchasesHistorical Data
16 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q3 '22 | Q4 '22 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $140.12M | $30.20M | $0.00 | $80.00M | $97.05M | $52.61M | $708.78M | $291.57M | $146.49M | $80.54M | $50.10M |
| QoQ Change | — | — | — | — | — | — | -78.4% | -100.0% | — | +21.3% | -45.8% | >999% | -58.9% | -49.8% | -45.0% | -37.8% |
| YoY Change | — | — | — | — | — | — | — | — | — | -30.7% | +74.2% | — | +264.5% | +51.0% | +53.1% | -92.9% |
Range$0.00 – $708.78M
Avg YoY Growth+53.2%
Median YoY Growth+52.0%
Current Streak4 quarters decline
Share Buybacks at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's share buybacks?
- Royalty Pharma (RPRX) reported share buybacks of $50.10M in Q1 2026.
- How has Royalty Pharma's share buybacks changed year-over-year?
- Royalty Pharma's share buybacks decreased by 92.9% year-over-year, from $708.78M to $50.10M.
- What does share buybacks mean?
- Cash spent by the company to buy back its own stock.